Register Login

Idarucizumab for Dabigatran Reversal

Melissa Thomas at Boehringer Ingelheim sent a press release about the report of their phase III trial, Idarucizumab for Dabigatran Reversal. The free full text article, Pollack CV, Reliiy PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal, NEJM 2015, DOI: 10.1056/NEJMoa1502000, is available from the NEJM web site.

Comments (0)
Anticoagulant Therapy

No comments here.

Leave a Reply